ABSTRACT
BACKGROUNDS Osteopetrosis, a rare skeletal disease, is characterized by an increased bone mass resulting from impaired bone remodeling process. Platelet is the major bone-healing blood component involved in the regulation of bone resorption, particularly in the removal of compromised bones. Several actin-associated proteins contribute to the orchestration of actin ring formation in osteoclasts closely related to bone resorption. However, the role of coactosin-like F-actin binding protein 1 (Cotl1) in actin ring formation and platelet-mediated bone resorption mechanisms remains unclear.
METHODS Whole-mount in situ RNA hybridization was performed to detect cotl1 expression pattern in zebrafish. cotl1 gene knockdown zebrafish using morpholino oligonucleotides and platelet marker-expressing transgenic zebrafish were investigated for finding the phenotypic clues. Cotl1 knockout (Cotl1-/-) mice were generated using Cre/loxP recombination systems. In silico network analysis of the differentially expressed genes between bone marrow samples of wild type and Cotl1-/- mice was conducted. Primary-cultured monocytes from Cotl1-/- mice were examined for osteoclast differentiation and mRNA and protein expression patterns. Cotl1-/- mice underwent hematological examination and bone phenotype assessments including micro-CT, bone density, histology, immunohistochemistry, electron microscopy, and mechanical testing. Genetic association of SNPs in human COTL1 gene with estimated bone mineral density was analyzed.
RESULTS Zebrafish cotl1 mRNA was highly expressed in the caudal hematopoietic tissue region. Knockdown of cotl1 in zebrafish embryos decreased the expression of c-myb, a marker of hematopoietic stem cells (HSCs). Notably, the platelet receptor CD41 was reduced in the HSCs of cotl1-depleted zebrafish and Cotl1-/- mice showed reduced platelet production with platelet surface markers of CD41 and CD61. Significantly reduced osteoclast differentiation and bone resorption pit, and impaired actin ring formation were observed in the primary myocytes from Cotl1-/- mice. Structural and histological analyses of the femur revealed sclerotic bone phenotypes in Cotl1-/- mice. Mechanical assessment of Cotl1-/- mouse femoral bones revealed osteopetrotic phenotypes. Association analysis of genetic variants in COTL1 gene in subjects from the UK Biobank suggested that COTL1 is susceptible to bone density in humans.
CONCLUSIONS Our results provide insights into the role of Cotl1 in platelet-mediated osteoclastogenesis and the novel finding that the loss of Cotl1-/- mice causes osteopetrosis phenotypes.
Clinical Perspective What Is New?
Deficiency of Cotl1 decreased platelet production in zebrafish and mice.
Absence of Cotl1 disrupted the actin ring formation which is crucial for osteoclast differentiation in bone remodeling process.
Cotl1 knockout mice displayed sclerotic bone phenotypes and increased bone density that are representative characteristics of osteopetrosis.
Genetic variants in COTL1 gene in subjects from the UK Biobank are significantly associated with bone density.
What Are the Clinical Implications?
The current findings suggest that Cotl1 plays a fundamental role in platelet production-mediated osteoclastogenesis during bone remodeling, providing valuable insights into novel strategies for bone health maintenance.
Cotl1 may be a promising target for novel therapeutic strategies for the treatment and/or prevention of impaired osteoclastogenesis-mediated bone diseases such as osteopetrosis and osteoporosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Research Foundation of Korea (NRF) grant (00250485) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institution (KHIDI), funded by the Ministry of Health & Welfare (HR22C1734) and by research fund of Ajou University Medical Center (M-2023-C0460-00079).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All animal research procedures were approved by the Animal Care and Use Committee of the Ajou University School of Medicine (IACUC No. 2021-0016). UK Biobank was granted ethical approval to collect participant data by the North West Multicenter Research Ethics Committee, the National Information Governance Board for Health & Social Care, and the Community Health Index Advisory Group (21/NW/0157).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data associated with this study are available from the corresponding author on reasonable request.
